[{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"||Somatostatin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Nestle Health Sciences SA \/ Codexis","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Codexis"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Carmot Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Carmot Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MHS552","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7204239","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

F. Hoffmann-La Roche

Switzerland

ESCRS

Not Confirmed

02

F. Hoffmann-La Roche

Switzerland

ESCRS

Not Confirmed

03

Nestle Health Sciences SA

Switzerland

ESCRS

Not Confirmed

04

Debiopharm

Switzerland

ESCRS

Not Confirmed

05

F. Hoffmann-La Roche

Switzerland

ESCRS

Not Confirmed

06

Debiopharm

Switzerland

ESCRS

Not Confirmed

07

Novartis Pharmaceuticals Corporation

Switzerland

ESCRS

Not Confirmed

08

Nestle Health Sciences SA

Switzerland

ESCRS

Not Confirmed

09

KeyBioscience

Switzerland

ESCRS

Not Confirmed

10

F. Hoffmann-La Roche

Switzerland

ESCRS

Not Confirmed

1
2